Conditions: Leukemia
Keywords: Acute myelogenous leukemia myelodysplastic Syndrome cancer
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 16
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the pharmacokinetics (PK) of decitabine administered to patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Decitabine (Dacogen)
Intervention descriptions: intervention 1: Intravenous injection; total dose-per-cycle was 135 mg/m\^2 of decitabine.

Protocol document: